Quarterly report · Q3
4978.TEDINET S100Q5XB
Period2022-04-01 → 2022-12-31
Filed2023-02-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.2bn | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Revenue | ¥2.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.5bn | 2021-04-01 → 2021-12-31 | Cons. | Net sales |
| Operating income | −¥207m | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Operating income | −¥529m | 2021-04-01 → 2021-12-31 | Cons. | Operating income |
| Ordinary income | −¥37m | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Ordinary income | −¥507m | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥351m | 2021-04-01 → 2021-12-31 | Cons. | Ordinary income |
| Profit before tax | −¥37m | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Profit before tax | −¥351m | 2021-04-01 → 2021-12-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥39m | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥575m | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥351m | 2021-04-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥39m | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Net income | −¥353m | 2021-04-01 → 2021-12-31 | Cons. | Profit loss |
| Total assets | ¥8.3bn | at 2022-12-31 | Cons. | Assets |
| Total assets | ¥8.1bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥7.8bn | at 2021-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥557m | at 2022-12-31 | Cons. | Liabilities |
| Total liabilities | ¥845m | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥7.7bn | at 2022-12-31 | Cons. | Net assets |
| Net assets / equity | ¥7.3bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥7.3bn | at 2021-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.4bn | at 2022-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.6bn | at 2022-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥-0.47 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.27 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-7.57 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-4.74 | 2021-04-01 → 2021-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.93 | 2021-10-01 → 2021-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 93.3% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.5% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 92.7% | at 2021-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment ordinary income | 2022-04-01 → 2022-12-31 | −¥440m |
| jpcrp040300-q3r_E27585-000Medical Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥866m |
| jpcrp040300-q3r_E27585-000Medical Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥866m |
| jpcrp040300-q3r_E27585-000Medical Businessreportable segment | segment ordinary income | 2022-04-01 → 2022-12-31 | ¥204m |
| jpcrp040300-q3r_E27585-000Research Support Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥1.4bn |
| jpcrp040300-q3r_E27585-000Research Support Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥1.4bn |
| jpcrp040300-q3r_E27585-000Research Support Businessreportable segment | segment ordinary income | 2022-04-01 → 2022-12-31 | ¥200m |
| —segment total | revenue | 2022-04-01 → 2022-12-31 | ¥2.2bn |
| —segment total | revenue external | 2022-04-01 → 2022-12-31 | ¥2.2bn |
| —segment total | segment ordinary income | 2022-04-01 → 2022-12-31 | ¥404m |
| Reconciling Itemsreconciling | segment ordinary income | 2021-04-01 → 2021-12-31 | −¥390m |
| jpcrp040300-q3r_E27585-000Medical Businessreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥514m |
| jpcrp040300-q3r_E27585-000Medical Businessreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥514m |
| jpcrp040300-q3r_E27585-000Medical Businessreportable segment | segment ordinary income | 2021-04-01 → 2021-12-31 | −¥50m |
| jpcrp040300-q3r_E27585-000Research Support Businessreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥975m |
| jpcrp040300-q3r_E27585-000Research Support Businessreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥975m |
| jpcrp040300-q3r_E27585-000Research Support Businessreportable segment | segment ordinary income | 2021-04-01 → 2021-12-31 | ¥89m |
| —segment total | revenue | 2021-04-01 → 2021-12-31 | ¥1.5bn |
| —segment total | revenue external | 2021-04-01 → 2021-12-31 | ¥1.5bn |
| —segment total | segment ordinary income | 2021-04-01 → 2021-12-31 | ¥39m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 355
| Item | Context | Value | Unit |
|---|---|---|---|
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |